Herpes Zoster (Shingles) - Pipeline Review, H2 2016

Date: September 28, 2016
Pages: 75
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H72B9D6F2F3EN
Leaflet:

Download PDF Leaflet

Herpes Zoster (Shingles) - Pipeline Review, H2 2016
Herpes Zoster (Shingles) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Herpes Zoster (Shingles) - Pipeline Review, H2 2016’, provides an overview of the Herpes Zoster (Shingles) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
  • The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects
  • The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) Overview
Therapeutics Development
Pipeline Products for Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics under Development by Companies
Herpes Zoster (Shingles) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Herpes Zoster (Shingles) - Products under Development by Companies
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
Beijing Minhai Biotechnology Co., Ltd
ContraVir Pharmaceuticals, Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
GeneOne Life Science, Inc.
GlaxoSmithKline Plc
Merck & Co., Inc.
N & N Pharmaceuticals Inc.
NAL Pharmaceuticals Ltd.
NanoViricides, Inc.
ReceptoPharm, Inc.
TSRL, Inc.
XBiotech Inc
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
acyclovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amenamevir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FV-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1437173A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3221 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3223 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPI-78M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
Oct 27, 2015: GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
Sep 08, 2015: Clinical trial for Cardiff’s shingles treatment
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
Apr 09, 2013: Zoster Vaccine Effective Against Incident Herpes Zoster And Post-herpetic Neuralgia In Older US Population, Cohort Study Finds
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Herpes Zoster (Shingles), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016
Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2016
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by N & N Pharmaceuticals Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
Herpes Zoster (Shingles) - Pipeline by NanoViricides, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by ReceptoPharm, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H2 2016
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Herpes Zoster (Shingles) - Dormant Projects, H2 2016
Herpes Zoster (Shingles) - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Herpes Zoster (Shingles), H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Astellas Pharma Inc.
Beijing Minhai Biotechnology Co., Ltd
ContraVir Pharmaceuticals, Inc.
Epiphany Biosciences, Inc.
Foamix Pharmaceuticals Ltd.
GeneOne Life Science, Inc.
GlaxoSmithKline Plc
Merck & Co., Inc.
N & N Pharmaceuticals Inc.
NAL Pharmaceuticals Ltd.
NanoViricides, Inc.
ReceptoPharm, Inc.
TSRL, Inc.
XBiotech Inc
Skip to top


Herpes zoster infections Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 91 pages

Ask Your Question

Herpes Zoster (Shingles) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: